ストックスクリーナーアプリを入手
7.93
4.07%
0.31
プレマーケット:
7.71
-0.22
-2.77%
前日終値:
$7.62
開ける：
$7.71
24時間の取引高:
640.37K
Relative Volume:
0.68
時価総額：
$326.05M
収益：
$142.09M
当期純損益:
$-35.73M
株価収益率:
-9.0298
EPS:
-0.8782
ネットキャッシュフロー:
$-22.20M
1週間 パフォーマンス:
-9.99%
1か月 パフォーマンス:
-0.13%
6か月 パフォーマンス:
-6.38%
1年 パフォーマンス:
-70.48%
1日の値動き範囲:
$7.5925
$8.01
1週間の範囲:
$7.135
$9.00
52週間の値動き範囲:
$6.32
$27.13
Rxsight Inc Stock (RXST) Company Profile
Compare RXST vs ABT, SYK, MDT, BSX, EW
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
RXST
Rxsight Inc
|
7.93 | 313.31M | 142.09M | -35.73M | -22.20M | -0.8782 |
|
ABT
Abbott Laboratories
|
113.10 | 197.42B | 44.33B | 6.50B | 7.40B | 3.717 |
|
SYK
Stryker Corp
|
381.89 | 147.18B | 25.12B | 3.25B | 4.28B | 8.3984 |
|
MDT
Medtronic Plc
|
95.60 | 124.16B | 35.48B | 4.64B | 5.41B | 3.582 |
|
BSX
Boston Scientific Corp
|
72.21 | 109.58B | 20.08B | 2.89B | 3.66B | 1.9391 |
|
EW
Edwards Lifesciences Corp
|
85.22 | 49.49B | 6.07B | 1.06B | 1.34B | 1.8063 |
Rxsight Inc Stock (RXST) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-01-30 | 開始されました | William Blair | Mkt Perform |
| 2025-07-15 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2025-07-10 | ダウングレード | Jefferies | Buy → Hold |
| 2025-07-09 | ダウングレード | BTIG Research | Buy → Neutral |
| 2025-07-09 | ダウングレード | Oppenheimer | Outperform → Perform |
| 2025-07-09 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2025-05-19 | アップグレード | Wells Fargo | Equal Weight → Overweight |
| 2025-04-15 | 開始されました | Piper Sandler | Neutral |
| 2025-04-09 | ダウングレード | UBS | Buy → Neutral |
| 2025-04-04 | ダウングレード | JP Morgan | Overweight → Underweight |
| 2025-04-03 | ダウングレード | BofA Securities | Buy → Underperform |
| 2024-12-20 | ダウングレード | Stifel | Buy → Hold |
| 2024-12-11 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2024-12-06 | 開始されました | UBS | Buy |
| 2024-10-29 | 開始されました | Jefferies | Buy |
| 2024-08-20 | 繰り返されました | Needham | Buy |
| 2024-08-06 | 繰り返されました | Needham | Buy |
| 2024-05-07 | 繰り返されました | BTIG Research | Buy |
| 2023-12-13 | アップグレード | Wells Fargo | Equal Weight → Overweight |
| 2023-12-12 | 開始されました | Stifel | Buy |
| 2023-12-04 | 開始されました | Morgan Stanley | Overweight |
| 2023-04-13 | 開始されました | Oppenheimer | Outperform |
| 2022-12-12 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2022-04-08 | 開始されました | Needham | Buy |
すべてを表示
Rxsight Inc (RXST) 最新ニュース
Midday Stock Roundup: Evolus, Xponential up - Orange County Business Journal
Forecast Cut: Will RxSight Inc stock go up in YEARJuly 2025 Outlook & High Return Stock Watch Alerts - baoquankhu1.vn
RxSight (RXST) Q4 2025 Earnings Call Transcript - AOL.com
RxSight (RXST) CCO gains 6,261 shares, withholds 2,580 for taxes - Stock Titan
RXST Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Short Interest in RxSight, Inc. (NASDAQ:RXST) Expands By 29.3% - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Encourages RxSight, Inc. (RXST) Shareholders to Inquire about Securities Investigation - ACCESS Newswire
2026-03-01 | Bronstein, Gewirtz & Grossman, LLC Encourages RxSight, Inc. (RXST) Shareholders to Inquire about Securities Investigation | NDAQ:RXST | Press Release - Stockhouse
Artisan Partners Limited Partnership Cuts Position in RxSight, Inc. $RXST - MarketBeat
RXST Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
RxSight, Inc. (RXST) Investor Outlook: Exploring a 28% Potential Upside in the Medical Devices Sector - DirectorsTalk Interviews
RxSight, Inc. (NASDAQ:RXST) Q4 2025 Earnings Call Transcript - Insider Monkey
RxSight Reports Fourth Quarter and Fiscal Year Financial Results - VisionMonday.com
Responsive Playbooks and the RXST Inflection - Stock Traders Daily
Needham reiterates Buy on RxSight stock, keeps $13 target By Investing.com - Investing.com Australia
What 5 Analyst Ratings Have To Say About RxSight - Benzinga
UBS Increases Price Target for RXST to $9.00 While Maintaining N - GuruFocus
RxSight (NASDAQ:RXST) Given New $9.00 Price Target at UBS Group - MarketBeat
RXST: Piper Sandler Lowers Price Target to $10.00, Maintains Neu - GuruFocus
RxSight (NASDAQ:RXST) Price Target Lowered to $10.00 at Piper Sandler - MarketBeat
UBS Adjusts Price Target on RxSight to $9 From $8, Maintains Neutral Rating - marketscreener.com
RxSight, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
Needham Reiterates Buy Rating on RxSight Inc. (RXST) - StreetInsider
RxSight Q4 Earnings Call Highlights - MarketBeat
RxSight (NASDAQ:RXST) Issues Earnings Results - MarketBeat
RxSight, Inc. (RXST) Posts Fourth Quarter Loss, Surpasses Revenue Expectations - Bitget
Earnings call transcript: RxSight Q4 2025 beats EPS, revenue forecasts - Investing.com
RxSight, Inc. (RXST) Reports Q4 Loss, Beats Revenue Estimates - Yahoo Finance
RXSIGHT INC (NASDAQ:RXST) Reports Q4 Beat but Cautious 2026 Outlook Weighs on Shares - ChartMill
Earnings call transcript: RxSight Q4 2025 beats EPS, revenue forecasts By Investing.com - Investing.com South Africa
RxSight, Inc. (RXST) Tops Q4 EPS by 32c - StreetInsider
RxSight (RXST) Releases Q4 2025 Earnings: Revenue Down but Beats Estimates; Loss Narrows, EPS Beats - Quiver Quantitative
RxSight, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
RXSight, Inc. Reports Fourth Quarter and 2025 Results; Issues 2026 Guidance - The Manila Times
RxSight (RXST) grows LAL volume but posts wider 2025 loss, soft 2026 outlook - Stock Titan
RxSight, Inc. Provides Earnings Guidance for the Full Year 2026 - marketscreener.com
Earnings Update: Will RxSight Inc face regulatory challenges2025 Year in Review & Low Drawdown Trading Strategies - baoquankhu1.vn
Bronstein, Gewirtz & Grossman, LLC Is Investigating RxSight, Inc. (RXST) And Encourages Investors to Connect - Stockhouse
Earnings To Watch: RxSight Inc (RXST) Reports Q4 2025 Result - GuruFocus
Analyst Calls: Can ProQR Therapeutics NV withstand a market correctionBuy Signal & Daily Momentum Trading Reports - baoquankhu1.vn
2026-02-22 | Bronstein, Gewirtz & Grossman, LLC Encourages RxSight, Inc. (RXST) Stockholders to Inquire about Securities Investigation | NDAQ:RXST | Press Release - Stockhouse
RxSight, Inc. (RXST) initiated at market perform as firm seeks sales reacceleration - MSN
Analysts Offer Insights on Healthcare Companies: RxSight (RXST), Senseonics Holdings (SENS) and Novo Nordisk (NVO) - The Globe and Mail
RxSight, Inc. (RXST) Stock Analysis: A Closer Look At The 23.68% Potential Upside - DirectorsTalk Interviews
RxSight, Inc. (NASDAQ:RXST) Given Average Recommendation of "Reduce" by Brokerages - MarketBeat
Will RxSight Inc. benefit from AI trendsWeekly Trend Report & AI Enhanced Trading Signals - mfd.ru
Will RxSight Inc. outperform tech stocksJuly 2025 Action & Entry Point Confirmation Alerts - mfd.ru
Can RxSight Inc. deliver consistent EPS growth2025 Retail Activity & Safe Swing Trade Setup Alerts - mfd.ru
Earnings Preview: Teleflex (TFX) Q4 Earnings Expected to Decline - Finviz
2026-02-19 | Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against RxSight, Inc. (RXST) and Encourages Investors to Learn More About the Investigation | NDAQ:RXST | Press Release - Stockhouse
Earnings Preview: RxSight, Inc. (RXST) Q4 Earnings Expected to Decline - Finviz
Rxsight Inc (RXST) 財務データ
収益
当期純利益
現金流量
EPS
2.27%
1.94%
大文字化:
|
ボリューム (24 時間):